Announcement of Intent To Establish the Tick-Borne Disease Working Group and Solicitation of Nominations for Appointment to the Working Group Membership, 32711-32712 [2017-14965]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
Dated: July 10, 2017.
Mary Lazare,
Acting Administrator and Assistant Secretary
for Aging.
[FR Doc. 2017–14960 Filed 7–14–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Announcement of Intent To Establish
the Tick-Borne Disease Working Group
and Solicitation of Nominations for
Appointment to the Working Group
Membership
Office of the Assistant
Secretary for Health, Office of the
Secretary, U.S. Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services (HHS)
announces establishment of the
Working Group. The Secretary of Health
and Human Services is responsible for
ensuring the conduct of and support for
epidemiological, basic, translational,
and clinical research related to vectorborne diseases, including tick-borne
diseases.
The Working Group will assist in this
effort. The Working Group will consist
of representatives of appropriate federal
agencies and non-federal entities who
represent diverse scientific disciplines
and views. The Working Group will
provide expertise and review all efforts
within the Department of Health and
Human Services related to all tick-borne
diseases, to help ensure interagency
coordination and minimize overlap, and
to examine research priorities.
This notice also will serve to
announce that HHS is seeking
nominations of individuals who are
interested in being considered for
appointment to the Working Group.
Resumes or curricula vitae from
qualified individuals who wish to be
considered for appointment as a
member of the Working Group are
currently being accepted.
DATES: Nominations must be received
no later than close of business August
16, 2017.
ADDRESSES: All nominations should be
sent to: CAPT Richard Henry, Office of
HIV/AIDS and Infectious Disease Policy,
Office of the Assistant Secretary for
Health, U.S. Department of Health and
Human Services, 330 C Street SW.,
Room L001 Switzer Building,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
CAPT Richard Henry, Office of HIV/
AIDS and Infectious Disease Policy;
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
Telephone: (202) 795–7615; Fax: (202)
691–2101; Email address:
richard.henry@hhs.gov. When the
charter for the Working Group has been
filed with the appropriate Congressional
committees and the Library of Congress,
this document will be made available
online. Web site information about
activities of the Working Group will be
provided when the URL has been
identified. The charter will include
detailed information about the purpose,
function, and structure of the Working
Group.
SUPPLEMENTARY INFORMATION: Section
2062 of the 21st Century Cures Act
authorizes establishment of the TickBorne Disease Working Group (Working
Group). The Working Group will be
governed by provisions of the Federal
Advisory Committee Act, Public Law
92–463, as amended (5 U.S.C. App.),
which sets forth standards for the
formation and use of federal advisory
committees.
The 21st Century Cures Act is
intended to advance the research and
development of new therapies and
diagnostics and make substantial federal
investments in a wide range of health
priorities.
Under Section 2062 of the 21st
Century Cures Act, it is mandated that
the Secretary of Health and Human
Services establish the Working Group.
The Working Group will be comprised
of representatives of appropriate federal
agencies and non-federal entities. The
Working Group membership will
represent diverse scientific disciplines
and views.
The charter for the Working Group
has been drafted. When the charter is
approved, it will be filed with the
appropriate Congressional committees
and the Library of Congress; hard copies
of this document will be made available
upon request. The approved charter also
will be accessible on line. The Working
Group will be established as a nondiscretionary federal advisory
committee.
Objectives and Scope of Activities.
The Secretary of Health and Human
Services is responsible for ensuring the
conduct of and support for
epidemiological, basic, translational,
and clinical research related to vectorborne diseases, including tick-borne
diseases. The Working Group will
provide assistance for this effort. The
Working Group membership will
provide expertise and will review all
efforts within the Department of Health
and Human Services related to all tickborne diseases, to help ensure
interagency coordination and minimize
overlap, and to examine research
priorities.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
32711
Membership and Designation. The
Working Group will consist of 14 voting
members who represent diverse
scientific disciplines and views. The
composition will include seven federal
members and seven non-federal public
members. The federal members will
consist of one or more representatives of
each of the following: Office of the
Assistant Secretary for Health, the Food
and Drug Administration, the Centers
for Disease Control and Prevention, and
the National Institutes of Health. The
non-federal public members will consist
of representatives of the following
categories: Physicians and other medical
providers with experience in diagnosing
and treating tick-borne diseases;
scientists or researchers with expertise;
patients and their family members;
nonprofit organizations that advocate
for patients with respect to tick-borne
disease. Individuals who are appointed
to represent federal entities will be
classified as regular government
employees. The non-federal public
members will be classified as special
government employees. Invitations of
membership will be extended to other
agencies and offices of the Department
of Health and Human Services and other
individuals as determined by the
Secretary to be appropriate and
beneficial for accomplishing the mission
of the Working Group.
The federal members will be
appointed to serve for the duration of
time that the Working Group is
authorized to operate. Participation of
the appointed federal members will be
at the discretion of their respective
agency head. The non-federal public
members will be invited to serve
overlapping terms of up to four years.
Any non-federal public member who is
appointed to fill the vacancy of an
unexpired term will be appointed to
serve for the remainder of that term. A
non-federal public member may serve
after the expiration of their term until
their successor has taken office, but no
longer than 180 days. Terms of more
than two years are contingent upon
renewal of the charter of the Working
Group.
Pursuant to advance written
agreement, non-federal public members
of the Working Group will receive no
stipend for the advisory service that
they render as members of the Working
Group. However, non-federal public
members will receive per diem and
reimbursement for travel expenses
incurred in relation to performing duties
for the Working Group, as authorized by
law under 5 U.S.C. 5703 for persons
who are employed intermittently to
perform services for the federal
E:\FR\FM\17JYN1.SGM
17JYN1
32712
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
asabaliauskas on DSKBBXCHB2PROD with NOTICES
government and in accordance with
federal travel regulations.
Estimated Number and Frequency of
Meetings. The Working Group will meet
not less than twice a year. The meetings
will be open to the public, except as
determined otherwise by the Secretary,
or another official to whom authority
has been delegated, in accordance with
the guidelines under Government in the
Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations, including
self-nominations, of individuals who
have the specified expertise and
knowledge will be considered for
appointment as public voting members
of the Working Group. A nomination
should include, at a minimum, the
following for each nominee: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination, and a
statement from the nominee that
indicates that the individual is willing
to serve as a member of the Working
Group, if selected; (2) the nominator’s
name, address, and daytime telephone
number, and the address, telephone
number, and email address of the
individual being nominated; and (3) a
current copy of the nominee’s
curriculum vitae or resume, which
should be limited to no more than 10
pages.
Every effort will be made to ensure
that the Working Group is a diverse
group of individuals with representation
from various geographic locations, racial
and ethnic minorities, all genders, and
persons living with disabilities.
Individuals being considered for
appointment as public voting members
will be required to complete and submit
a report of their financial holdings. An
ethics review must be conducted to
ensure that individuals appointed as
public voting members of the Working
Group are not involved in any activity
that may pose a potential conflict of
interest for the official duties that are to
be performed. This is a federal ethics
requirement that must be satisfied upon
entering the position and annually
throughout the established term of
appointment on the Working Group.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Prospective Grant of Exclusive Patent
License: Development, Commercial
Application and Use of Fulvestrant in
Combination Therapy for the
Treatment of Cancers
Dated: July 12, 2017.
Donald Wright,
Acting Assistant Secretary for Health.
[FR Doc. 2017–14857 Filed 7–14–17; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: July 31, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D., AIDS
Review Branch, Scientific Review Program,
Division of Extramural Activities, Room
#3G11B, National Institutes of Health, NIAID,
5601 Fishers Lane MSC–9823, Bethesda, MD
20892–9823, (240) 669–5046, jay.radke@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2017–14965 Filed 7–14–17; 8:45 am]
BILLING CODE 4150–28–P
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the U.S. Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to NantBioScience, Inc.,
located in, California, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before August 1, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Sabarni
K. Chatterjee, Ph.D., M.B.A., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240) 276–5530;
Facsimile: (240) 276–5504 Email:
sabarni.chatterjee@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
• United States Provisional Patent
Application No. 62/290,117 filed
February 02, 2016, and entitled
‘‘Fulvestrant Improves Immunemediated Cytotoxic Lysis of Cancer
Cells.’’ [HHS Reference No. E–066–
2016/0–US–01];
• International PCT Application No.
PCT/US2017/015829 filed January 31,
2017, entitled ‘‘Fulvestrant Improves
Immune-mediated Cytotoxic Lysis of
Cancer Cells.’’ [HHS Reference No. E–
066–2016/0–PCT–02]; and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
E:\FR\FM\17JYN1.SGM
17JYN1
]]>Agencies
[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Notices]
[Pages 32711-32712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14965]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Announcement of Intent To Establish the Tick-Borne Disease
Working Group and Solicitation of Nominations for Appointment to the
Working Group Membership
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, U.S. Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services (HHS)
announces establishment of the Working Group. The Secretary of Health
and Human Services is responsible for ensuring the conduct of and
support for epidemiological, basic, translational, and clinical
research related to vector-borne diseases, including tick-borne
diseases.
The Working Group will assist in this effort. The Working Group
will consist of representatives of appropriate federal agencies and
non-federal entities who represent diverse scientific disciplines and
views. The Working Group will provide expertise and review all efforts
within the Department of Health and Human Services related to all tick-
borne diseases, to help ensure interagency coordination and minimize
overlap, and to examine research priorities.
This notice also will serve to announce that HHS is seeking
nominations of individuals who are interested in being considered for
appointment to the Working Group. Resumes or curricula vitae from
qualified individuals who wish to be considered for appointment as a
member of the Working Group are currently being accepted.
DATES: Nominations must be received no later than close of business
August 16, 2017.
ADDRESSES: All nominations should be sent to: CAPT Richard Henry,
Office of HIV/AIDS and Infectious Disease Policy, Office of the
Assistant Secretary for Health, U.S. Department of Health and Human
Services, 330 C Street SW., Room L001 Switzer Building, Washington, DC
20201.
FOR FURTHER INFORMATION CONTACT: CAPT Richard Henry, Office of HIV/AIDS
and Infectious Disease Policy; Telephone: (202) 795-7615; Fax: (202)
691-2101; Email address: richard.henry@hhs.gov. When the charter for
the Working Group has been filed with the appropriate Congressional
committees and the Library of Congress, this document will be made
available online. Web site information about activities of the Working
Group will be provided when the URL has been identified. The charter
will include detailed information about the purpose, function, and
structure of the Working Group.
SUPPLEMENTARY INFORMATION: Section 2062 of the 21st Century Cures Act
authorizes establishment of the Tick-Borne Disease Working Group
(Working Group). The Working Group will be governed by provisions of
the Federal Advisory Committee Act, Public Law 92-463, as amended (5
U.S.C. App.), which sets forth standards for the formation and use of
federal advisory committees.
The 21st Century Cures Act is intended to advance the research and
development of new therapies and diagnostics and make substantial
federal investments in a wide range of health priorities.
Under Section 2062 of the 21st Century Cures Act, it is mandated
that the Secretary of Health and Human Services establish the Working
Group. The Working Group will be comprised of representatives of
appropriate federal agencies and non-federal entities. The Working
Group membership will represent diverse scientific disciplines and
views.
The charter for the Working Group has been drafted. When the
charter is approved, it will be filed with the appropriate
Congressional committees and the Library of Congress; hard copies of
this document will be made available upon request. The approved charter
also will be accessible on line. The Working Group will be established
as a non-discretionary federal advisory committee.
Objectives and Scope of Activities. The Secretary of Health and
Human Services is responsible for ensuring the conduct of and support
for epidemiological, basic, translational, and clinical research
related to vector-borne diseases, including tick-borne diseases. The
Working Group will provide assistance for this effort. The Working
Group membership will provide expertise and will review all efforts
within the Department of Health and Human Services related to all tick-
borne diseases, to help ensure interagency coordination and minimize
overlap, and to examine research priorities.
Membership and Designation. The Working Group will consist of 14
voting members who represent diverse scientific disciplines and views.
The composition will include seven federal members and seven non-
federal public members. The federal members will consist of one or more
representatives of each of the following: Office of the Assistant
Secretary for Health, the Food and Drug Administration, the Centers for
Disease Control and Prevention, and the National Institutes of Health.
The non-federal public members will consist of representatives of the
following categories: Physicians and other medical providers with
experience in diagnosing and treating tick-borne diseases; scientists
or researchers with expertise; patients and their family members;
nonprofit organizations that advocate for patients with respect to
tick-borne disease. Individuals who are appointed to represent federal
entities will be classified as regular government employees. The non-
federal public members will be classified as special government
employees. Invitations of membership will be extended to other agencies
and offices of the Department of Health and Human Services and other
individuals as determined by the Secretary to be appropriate and
beneficial for accomplishing the mission of the Working Group.
The federal members will be appointed to serve for the duration of
time that the Working Group is authorized to operate. Participation of
the appointed federal members will be at the discretion of their
respective agency head. The non-federal public members will be invited
to serve overlapping terms of up to four years. Any non-federal public
member who is appointed to fill the vacancy of an unexpired term will
be appointed to serve for the remainder of that term. A non-federal
public member may serve after the expiration of their term until their
successor has taken office, but no longer than 180 days. Terms of more
than two years are contingent upon renewal of the charter of the
Working Group.
Pursuant to advance written agreement, non-federal public members
of the Working Group will receive no stipend for the advisory service
that they render as members of the Working Group. However, non-federal
public members will receive per diem and reimbursement for travel
expenses incurred in relation to performing duties for the Working
Group, as authorized by law under 5 U.S.C. 5703 for persons who are
employed intermittently to perform services for the federal
[[Page 32712]]
government and in accordance with federal travel regulations.
Estimated Number and Frequency of Meetings. The Working Group will
meet not less than twice a year. The meetings will be open to the
public, except as determined otherwise by the Secretary, or another
official to whom authority has been delegated, in accordance with the
guidelines under Government in the Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations, including self-nominations, of
individuals who have the specified expertise and knowledge will be
considered for appointment as public voting members of the Working
Group. A nomination should include, at a minimum, the following for
each nominee: (1) A letter of nomination that clearly states the name
and affiliation of the nominee, the basis for the nomination, and a
statement from the nominee that indicates that the individual is
willing to serve as a member of the Working Group, if selected; (2) the
nominator's name, address, and daytime telephone number, and the
address, telephone number, and email address of the individual being
nominated; and (3) a current copy of the nominee's curriculum vitae or
resume, which should be limited to no more than 10 pages.
Every effort will be made to ensure that the Working Group is a
diverse group of individuals with representation from various
geographic locations, racial and ethnic minorities, all genders, and
persons living with disabilities.
Individuals being considered for appointment as public voting
members will be required to complete and submit a report of their
financial holdings. An ethics review must be conducted to ensure that
individuals appointed as public voting members of the Working Group are
not involved in any activity that may pose a potential conflict of
interest for the official duties that are to be performed. This is a
federal ethics requirement that must be satisfied upon entering the
position and annually throughout the established term of appointment on
the Working Group.
Dated: July 12, 2017.
Donald Wright,
Acting Assistant Secretary for Health.
[FR Doc. 2017-14965 Filed 7-14-17; 8:45 am]
BILLING CODE 4150-28-P
